Immunotherapy for advanced melanoma study
Treatments studied
Part of Cancer, Skin clinical trials.
This study tests how well immunotherapy drugs like pembrolizumab and nivolumab work for people with advanced melanoma that has spread. It aims to find markers that predict treatment response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have advanced melanoma that has spread to other parts of the body and cannot be surgically removed
- You have not had any previous treatment for advanced melanoma
- You are able to perform daily activities with little or no help (ECOG score 0-2)
- You do not have a weakened immune system or active autoimmune disease
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at tissue and scan-related markers (“biomarkers”) to better understand how immunotherapy works in people with advanced melanoma. You may receive standard first-line immunotherapy, and your recent scans and health details will help researchers study why some people respond better than others.
This study tests a combination of three drugs (relatlimab, ipilimumab, and nivolumab) as a first treatment for advanced melanoma that cannot be removed by surgery. All participants will receive the drug combination, and the study will look at safety and how well it works.
This Phase 2 trial studies a specific sequence of immune medicines for people with stage 3 or 4 melanoma that has spread or cannot be removed. It’s designed for melanoma that worsened after prior PD-1 treatment, aiming to shrink tumors and control disease.
This trial tests a combination of three immunotherapy drugs (fianlimab, cemiplimab, and ipilimumab) for people with advanced melanoma that has stopped responding to previous PD-1/PD-L1 treatment. It aims to see if this new combination can help shrink or control the cancer.
This trial tests whether giving immunotherapy before surgery and possibly skipping some after may help people with advanced but removable melanoma. It aims to see if this approach can reduce the chance of the cancer coming back.
This trial tests a treatment that uses your own immune cells, called tumor-infiltrating lymphocytes (TILs), to fight melanoma. Some participants also get a drug called pembrolizumab. The goal is to see if this approach can shrink tumors.
Hear when a new Metastatic Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.